LEE'S PHARM Reports Annual Results with HK$91.94 Million Attributable Profit

Stock News

Mar 30

LEE'S PHARM (00950) announced its annual results for the period ended December 31, 2025. The Group recorded revenue of HK$1.436 billion, representing a year-on-year increase of 2.6%. Profit attributable to shareholders was HK$91.938 million, a decrease of 1.2% compared to the previous year. Earnings per share stood at HK15.61 cents. The Board proposed a final dividend of HK2.3 cents per share. According to the announcement, the decline in profit attributable to owners of the company reflects the combined impact of a challenging market environment and increased research and development expenditure, which offset the benefits from revenue growth and reduced selling expenses, leading to the year-on-year decrease in net profit.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1139043376"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1139043376\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1139043376?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 17:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139043376","market":"us","top_or_hot":-1,"title":"LEE'S PHARM Reports Annual Results with HK$91.94 Million Attributable Profit","media":"Stock News","content":"<p>LEE'S PHARM (00950) announced its annual results for the period ended December 31, 2025. The Group recorded revenue of HK$1.436 billion, representing a year-on-year increase of 2.6%. Profit attributable to shareholders was HK$91.938 million, a decrease of 1.2% compared to the previous year. Earnings per share stood at HK15.61 cents. The Board proposed a final dividend of HK2.3 cents per share. According to the announcement, the decline in profit attributable to owners of the company reflects the combined impact of a challenging market environment and increased research and development expenditure, which offset the benefits from revenue growth and reduced selling expenses, leading to the year-on-year decrease in net profit.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LEE'S PHARM Reports Annual Results with HK$91.94 Million Attributable Profit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLEE'S PHARM Reports Annual Results with HK$91.94 Million Attributable Profit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-30 17:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LEE'S PHARM (00950) announced its annual results for the period ended December 31, 2025. The Group recorded revenue of HK$1.436 billion, representing a year-on-year increase of 2.6%. Profit attributable to shareholders was HK$91.938 million, a decrease of 1.2% compared to the previous year. Earnings per share stood at HK15.61 cents. The Board proposed a final dividend of HK2.3 cents per share. According to the announcement, the decline in profit attributable to owners of the company reflects the combined impact of a challenging market environment and increased research and development expenditure, which offset the benefits from revenue growth and reduced selling expenses, leading to the year-on-year decrease in net profit.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1139043376","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139043376","pubTimestamp":1774862555,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LEE'S PHARM (00950) announced its annual results for the period ended December 31, 2025. The Group recorded revenue of HK$1.436 billion, representing a year-on-year increase of 2.6%. Profit...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1587":"次新股","BK1574":"生物医药B类股","00950":"李氏大药厂","BK1583":"高瓴概念","06622":"兆科眼科-B"},"translate_title":"李氏大药厂公布全年业绩，应佔溢利为9194万港元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00950":1,"06622":1},"content_text":"LEE'S PHARM (00950) announced its annual results for the period ended December 31, 2025. The Group recorded revenue of HK$1.436 billion, representing a year-on-year increase of 2.6%. Profit attributable to shareholders was HK$91.938 million, a decrease of 1.2% compared to the previous year. Earnings per share stood at HK15.61 cents. The Board proposed a final dividend of HK2.3 cents per share. According to the announcement, the decline in profit attributable to owners of the company reflects the combined impact of a challenging market environment and increased research and development expenditure, which offset the benefits from revenue growth and reduced selling expenses, leading to the year-on-year decrease in net profit.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}